Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia

Letter Hematology

Daratumumab for refractory warm autoimmune hemolytic anemia

Ankur Jain et al.

ANNALS OF HEMATOLOGY (2021)

Article Immunology

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease

Anna Zaninoni et al.

Summary: Daratumumab, a monoclonal antibody targeting CD38, has shown efficacy in multiple myeloma and is now being investigated for its potential in treating autoimmune conditions like cold agglutinin disease. The drug not only depletes plasma cells but also demonstrates immunomodulatory effects by influencing the levels of various cytokines. Research also suggests its potential in refractory autoimmune hemolytic anemia, Evans syndrome, and other autoimmune diseases.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Pediatrics

Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature

Lina Driouk et al.

Summary: Immune-mediated cytopenias following HSCT are challenging complications. While corticosteroids are standard treatment, novel therapies like daratumumab show promise for steroid-refractory cases. Limited data warrants further controlled trials to assess safety and efficacy.

MOLECULAR AND CELLULAR PEDIATRICS (2021)

Add to Collection

Article Pediatrics

A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

Claire Dossier et al.

Summary: The study demonstrates that a global antiB cell strategy combining obinutuzumab and daratumumab can induce prolonged peripheral B cell depletion and remission in children with difficult-to-treat SDNS.

PEDIATRIC NEPHROLOGY (2021)

Add to Collection

Article Oncology